Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials

E-ISSN： 1875-6417|13|4|405-423

ISSN： 1573-3998

Source： Current Diabetes Reviews, Vol.13, Iss.4, 2017-07, pp. : 405-423

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical overview of linagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with Type 2 diabetes mellitus

By Forst Thomas Pfützner Andreas

Expert Review of Endocrinology and Metabolism, Vol. 8, Iss. 1, 2013-01 ,pp. : 21-35

Informa Healthcare

Access to resources Recommend Favorite

Clinical Science of Type 2 Diabetes Mellitus

By Salans L.B.

Trends in Endocrinology and Metabolism, Vol. 9, Iss. 1, 1998-01 ,pp. : 43-44

Elsevier

Access to resources Recommend Favorite

Efficacy and safety of lixisenatide in the treatment of Type 2 diabetes mellitus: a review of Phase III clinical data

By Raccah Denis

Expert Review of Endocrinology and Metabolism, Vol. 8, Iss. 2, 2013-03 ,pp. : 105-121

Informa Healthcare

Access to resources Recommend Favorite

Alterations of Glucose Metabolism in Type 2 Diabetes Mellitus. An Overview

By Bonadonna Riccardo C.

Reviews in Endocrine and Metabolic Disorders, Vol. 5, Iss. 2, 2004-05 ,pp. : 89-97

Springer Publishing Company

Access to resources Recommend Favorite

Overview of Current and Upcoming Strategies Implied for the Therapy of Type 2 Diabetes Mellitus

Current Diabetes Reviews, Vol. 10, Iss. 4, 2014-07 ,pp. : 275-282

Bentham Science Publishers

Access to resources Recommend Favorite